Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer

  • Authors:
    • Machiko Kurimoto
    • Michio Kimura
    • Eiseki Usami
    • Mina Iwai
    • Tatsuya Hirose
    • Shiori Kawachi
    • Tomoaki Yoshimura
  • View Affiliations

  • Published online on: May 30, 2017     https://doi.org/10.3892/mco.2017.1278
  • Pages: 125-130
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The recommended chemotherapy regimens for pancreatic cancer include the combination of 5-fluorouracil/leucovorin, oxaliplatin and irinotecan (FOLFIRINOX), nab‑paclitaxel (nab‑PTX) plus gemcitabine (GEM), GEM alone and tegafur/gimeracil/oteracil potassium (S‑1) alone. Although the cost‑effectiveness of metastatic pancreatic cancer chemotherapies has been extensively investigated, to the best of our knowledge, no study has specifically compared the cost‑effectiveness among FOLFIRINOX, nab‑PTX + GEM, GEM and S‑1 regimens to date. The aim of the present study was to examine the cost-effectiveness of these four regimens. The expected costs were calculated based on data from patients with metastatic pancreatic cancer who were treated with the FOLFIRINOX, nab‑PTX + GEM, GEM alone or S‑1 alone. The median survival time (MST) from randomized controlled trials in the literature was used to evaluate the therapeutic effect of these regimens. The cost‑effectiveness ratio was calculated using expected costs and MST for these four regimens. The expected costs per patient for the FOLFIRINOX, nab‑PTX + GEM, GEM or S‑1 regimens were ¥6,361,191.4, ¥4,802,063.6, ¥540,091.4 and ¥528,514.6, respectively, and the cost‑effectiveness ratios per month were ¥642,544.6/MST, ¥470,790.5/MST, ¥81,832.0/MST and ¥55,633.1/MST, respectively. In conclusion, the nab‑PTX + GEM and FOLFIRINOX regimens were associated with a high therapeutic efficacy and high cost. The GEM regimen exhibited a lower therapeutic efficacy compared with the nab‑PTX + GEM and FOLFIRINOX regimens, but the findings of this study indicated that the GEM and S‑1 regimens were the most cost‑effective regimens.
View References

Related Articles

Journal Cover

July 2017
Volume 7 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kurimoto, M., Kimura, M., Usami, E., Iwai, M., Hirose, T., Kawachi, S., & Yoshimura, T. (2017). Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer. Molecular and Clinical Oncology, 7, 125-130. https://doi.org/10.3892/mco.2017.1278
MLA
Kurimoto, M., Kimura, M., Usami, E., Iwai, M., Hirose, T., Kawachi, S., Yoshimura, T."Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer". Molecular and Clinical Oncology 7.1 (2017): 125-130.
Chicago
Kurimoto, M., Kimura, M., Usami, E., Iwai, M., Hirose, T., Kawachi, S., Yoshimura, T."Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer". Molecular and Clinical Oncology 7, no. 1 (2017): 125-130. https://doi.org/10.3892/mco.2017.1278